Impressive H1 2021 results30 Sep 2020 09:34
If you want to read impressive H1 results come back in a year's time but the SP will be over 30p :)
I suggest you look at what's ahead. Foundations have been placed.
- Cash balance to double by year end.
- Quarantine clinic to be fully booked for 2 years for convention trials. 20% utilisation to date produced €15m of revenue.
- Covid-19 trials cost >£7m and we'll be fully booked with those at the second to be announced quarantine clinic.
- Monetise two of our non-core assets, the 49% stake in Imutex and the 62.6% stake in PrEP.
- Open Orphan data platform commercialisation in Q4, with some of the world's largest wearable companies for disease progression data.
The covid trials are major upside here that's not priced in, expect government announcement on those soon and then watch the SP.